Oct 22, 2026 earnings call — Raised full-year revenue and EPS guidance
Raised full-year revenue guidance to $12.065 billion-$12.105 billion after Q3 revenues of $3.1 billion, up 10%.
Revenue $3.1B (est $3.1B) · EPS $3.00 (est $2.87) · Next-quarter revenue outlook $12.1B–$12.1B
Key quotes
"We remain deeply concerned that the data collection process this year was also flawed, and the resulting preliminary rate cuts for 2027 are excessive."
"Users of the Apple Health app will be able to seamlessly purchase, schedule, and receive test results for over 50 biomarkers, including ApoB and Lp(a), all within the app."
"We remain on track to deliver 3% in annual cost savings and productivity improvements through our Invigorate program."
Analyst Q&A 13
PAMA impact and offsets for 2027
Q (Ann Hynes · Mizuho): Analyst asked how much of the PAMA headwind they could offset and what other high-level headwinds and tailwinds to consider for 2027.
A: Management said the PAMA impact is expected to be roughly 1% of revenues next year. They plan to offset a portion but will not cut frontline staff or lab operations. They will give more clarity when they announce Q4 results.
"First of all, as we mentioned on the call, the impact from PAMA, we expect to be next year roughly 1% of revenues." — Sam Samad (CFO)
Sources of 5% volume growth
Q (Michael Cherny · Leerink Partners): Analyst wanted to know where the 5% volume growth is coming from and how much is execution versus market performance.
A: Management said the 5% volume growth is ex Fresenius and ex Corewell and reflects broad strength. They are seeing strong growth across physician, hospital reference, and consumer channels, with consumer growing north of 30%.
"As we look across the channels that we always talk about, our physician channel, our hospital channel, both reference and Co-Lab Solutions, and our consumer channel, we are seeing strong growth across all three." — Jim Davis (CEO·CHAIR)
Apple partnership ramp and consumer margins
Q (Erin Wright · Morgan Stanley): Analyst asked how the Apple Health partnership will ramp, how it differs from other wearables, and how material it could be; also asked about pricing in consumer business.
A: Management said the Apple partnership is in beta testing and expects to go live later this year, before the start of next year, but they cannot forecast uptake yet. They emphasized the consumer channel is margin-accretive and benefits from dense requisitions and no denials. They will update on uptake after launch, likely in January.
"It is in what I would call beta testing mode at this point, and they expect to go live at some point later this year, before the start of next year." — Jim Davis (CEO·CHAIR)
Volume leverage and Invigorate savings
Q (Tycho Peterson · Jefferies): Analyst asked how much of the 40 basis points margin improvement was from volume leverage versus the Invigorate program and about automation/AI effects.
A: Management said the margin gain is a combination of volume leverage in a fixed-cost business and Invigorate savings. Invigorate is targeted to offset wage inflation at about 3%, probably between 3% and 4% this year, which equates to roughly $120 million of pressure they address. They are continuing Invigorate and other efficiencies while noting higher fuel costs that they are offsetting.
"But our Invigorate program, we've always targeted for our Invigorate to offset wage inflation at 3%, probably north of 3% this year, somewhere between 3% and 4%." — Jim Davis (CEO·CHAIR)
ACA exchange impact and cybersecurity update
Q (Lu Li · BofA Global): Analyst asked about ACA exchange disenrollment impact in the second half and for more color on the 8-K cybersecurity filing and potential financial impact.
A: On ACA, management said requisition volume from exchange members was down about 11%, tests per requisition were up 8%, and the net test impact was about a 3% decline, equating to roughly a 10 basis point revenue loss—not material. On the 8-K, they said there was unauthorized access to a test ordering system, the incident has not materially disrupted operations, and the investigation is in early stages.
"This incident has not materially disrupted our business operations or our ability to serve physicians and patients." — Sam Samad (CFO)
RESULTS Act timing and offset modeling
Q (Lisa Gill · JPMorgan): Analyst asked whether management has quantified the RESULTS Act impact, whether PAMA might be delayed, and how to model offsets for 2027.
A: Management said CMS data overrepresented independent labs and they expect a CBO score in mid to late November, but they cannot give a probability of RESULTS Act inclusion or of another delay. They reiterated the PAMA impact is roughly 1% of revenues and said they will offset a portion but have not finalized the offset; they will provide firm details with January earnings. Sam added do not assume the full impact in models because there will be offsets.
"I cannot give you a probability of RESULTS Act getting included or the potential for another delay." — Jim Davis (CEO·CHAIR)
Why PAMA estimate rose
Q (Luke Sergott · Barclays): Analyst asked why the prior $100 million estimate increased to $125–165 million after sharpened analysis.
A: Management said their earlier $100 million-$120 million range was set before the latest data. The new data showed many codes being cut, including 775 codes facing the maximum 15% cut, which raised the estimate. They said they will keep pushing for the RESULTS Act given concerns about the data collection.
"775 of those, Luke, are going to face the maximum 15% cut." — Jim Davis (CEO·CHAIR)
Why DSO rose and outlook
Q (Sky · Piper Sandler): Analyst asked what drove the DSO increase in the quarter and how to think about its cadence over the next 12 months.
A: Management said DSOs are up about three days since year-end and that much of the change is mix-driven by more client-bill business with longer payment terms and fewer banking days in the quarter. They emphasized bad debt and patient price concessions have not shown any meaningful increase and they expect no material negative change going forward.
"For those two, bad debt and patient price concessions, we have not seen any meaningful increase on both of these." — Sam Samad (CFO)
Project Nova timing and PAMA on other contracts
Q (Elizabeth Anderson · Evercore): Analyst asked whether Nova investment is stable within quarters and whether PAMA affects other pricing beyond CLFS-tied contracts.
A: Management said Project Nova will have a $0.25 impact this year, with 70% of that in the second half and more tilted to Q4 as they move from design to build. They said PAMA's core impact is about $120 million from Medicare and straight Medicaid plans tied to Medicare, and only a very small minority of other health-plan contracts remain tied to Medicare fees.
"We expect this year that it's going to be a $0.25 impact." — Sam Samad (CFO)
Organic volume mix and rev per requisition
Q (Kevin Caliendo · UBS): Analyst asked about drivers of organic volume growth, weather effects, and why rev per requisition decelerated.
A: Management said organic volume was 5% and the quarter was a clean volume quarter with no meaningful weather impact. They explained rev per requisition growth slowed because hospital reference work included many single-test requisitions (Lp(a), Alzheimer's) and a cyclospora spurt of low-revenue single tests. They also noted a modest HIX impact of about 10 basis points in the quarter and sized Q4 HIX impact at 10–20 basis points.
"What we saw in the quarter, what was driving a bunch of that growth, was a lot of single test reqs from some very large health systems that were leveraging our Lp(a) business or leveraging our Alzheimer's business." — Jim Davis (CEO·CHAIR)
Sequential margin improvement reasons
Q (Jack Mann · Nephron): Analyst asked why margins improved sequentially when Q2 is usually the high watermark.
A: Management said margin improvement versus Q2 was driven in part by better margins on the Corewell and Fresenius partnerships as integration costs ease. They also saw some SG&A leverage and a favorable mark-to-market on supplemental deferred compensation that boosted Q3 margins versus Q2. Overall there was nothing materially different beyond those items.
"We did have the improvement in the margins on Corewell and Fresenius helping us as we go from Q2-Q3." — Sam Samad (CFO)
PAMA multi-year impact details
Q (Yoojin Park · Baird): Analyst asked about the 1.3% cumulative revenue impact across 2027–2029 and wanted detail on year two and three.
A: Management said they will not provide a year-by-year breakdown for 2028 and 2029 right now. They are still analyzing the data and reiterated the estimate captures those years as part of the cumulative impact, with 2027 roughly a 1% revenue impact. They declined to give more granular guidance at this time.
"We're not going to provide a breakdown right now in terms of how that breaks down between 2028 and 2029." — Sam Samad (CFO)
Kidney care growth and go-to-market
Q (Jared Haase · William Blair): Analyst asked how management sees the growth opportunity in kidney care and whether it requires incremental commercial resources.
A: Management said the Fresenius dialysis testing work opened many new relationships with nephrologists, many of whom they did not previously serve. They have fielded a specialized sales force to call on nephrologists and offer cardiometabolic testing across early to late-stage kidney disease, and they expect this focused channel to create additional opportunities in 2027.
"So in fact, we have fielded a specialized sales force to call on nephrologists and offer a broad set of cardiometabolic testing associated with either early-stage kidney disease, mid-stage, or late-stage kidney disease." — Jim Davis (CEO·CHAIR)